Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Barr/AstraZeneca Tamoxifen Settlement Under Investigation By State AGs

Executive Summary

An inquiry by several states into Barr's tamoxifen agreement with AstraZeneca is the latest indication that states are not deferring to the Federal Trade Commission in investigating patent settlements.

You may also be interested in...



Barr/AstraZeneca tamoxifen antitrust suit dismissed

AstraZeneca and Barr "authorized generic" agreement for breast cancer agent Nolvadex did not violate antitrust laws, Brooklyn, N.Y. federal judge rules. Complaints from consumers and third-party payors argued that 1993 agreement under which Barr marketed generic tamoxifen until August 2002 kept other generics off market. Judge's ruling dismisses all state and federal claims. A prior Justice Department investigation into settlement was closed without action (1"The Pink Sheet" Sept. 3, 2001, p. 20)...

Barr/AstraZeneca tamoxifen antitrust suit dismissed

AstraZeneca and Barr "authorized generic" agreement for breast cancer agent Nolvadex did not violate antitrust laws, Brooklyn, N.Y. federal judge rules. Complaints from consumers and third-party payors argued that 1993 agreement under which Barr marketed generic tamoxifen until August 2002 kept other generics off market. Judge's ruling dismisses all state and federal claims. A prior Justice Department investigation into settlement was closed without action (1"The Pink Sheet" Sept. 3, 2001, p. 20)...

Barr Tamoxifen Supply Will Hold To Mid-Nov.; Firm Seeks FDA Injunction

Barr will be unable to supply tamoxifen 10 mg after mid-November in the absence of court action to overrule FDA and allow the immediate launch of the firm's generic

Related Content

UsernamePublicRestriction

Register

PS017586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel